Study backs prophylactic COVID-19 therapies in severe immunosuppression
Patients who fail to respond to vaccination could benefit from a 'timely' monoclonal antibody combination, a French study suggests
Patients with immune-mediated inflammatory diseases could be given prophylactic anti-SARS-CoV-2 monoclonal antibodies to lower their risk of severe disease, say French researchers.
Results from their world-first study published in The Lancet Rheumatology suggest that one third of severely immunocompromised individuals fail to mount an adequate humoral response to vaccination.
It is these patients, the authors explain, who stand to benefit from pre-exposure treatment with the anti-SARS
